TY  - JOUR
AU  - Merkies, Ingemar S J
AU  - van Schaik, Ivo N
AU  - Léger, Jean-Marc
AU  - Bril, Vera
AU  - van Geloven, Nan
AU  - Hartung, Hans-Peter
AU  - Lewis, Richard A
AU  - Sobue, Gen
AU  - Lawo, John-Philip
AU  - Durn, Billie L
AU  - Cornblath, David R
AU  - De Bleecker, Jan L
AU  - Sommer, Claudia
AU  - Robberecht, Wim
AU  - Saarela, Mika
AU  - Kamienowski, Jerzy
AU  - Stelmasiak, Zbigniew
AU  - Tackenberg, Björn
AU  - Mielke, Orell
AU  - PRIMA Trial Investigators and the PATH Study Group
PY  - 2019
DO  - 10.1111/jns.12302
UR  - http://hdl.handle.net/10668/13449
T2  - Journal of the peripheral nervous system : JPNS
AB  - Intravenous immunoglobulin (IVIG) is a potential therapy for chronic inflammatory demyelinating polyneuropathy (CIDP). To investigate the efficacy and safety of the IVIG IgPro10 (Privigen) for treatment of CIDP, results from Privigen Impact on...
LA  - en
KW  - CIDP
KW  - IVIG
KW  - PATH
KW  - PRIMA
KW  - efficacy
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Double-Blind Method
KW  - Europe
KW  - Female
KW  - Humans
KW  - Immunoglobulins, Intravenous
KW  - Immunologic Factors
KW  - Male
KW  - Middle Aged
KW  - Outcome Assessment, Health Care
KW  - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
KW  - Prospective Studies
KW  - Young Adult
TI  - Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
TY  - research article
VL  - 24
ER  -